Physician profile
Tamara Zach
NPI 1962638254
$9,728.03
in general payments reported to CMS, 2019-2025
27 companies · $6,409 in 2025
The $6,409 reported for 2025 was more than what 87% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $331 · 2021: $443 · 2022: $481 · 2023: $776 · 2024: $820 · 2025: $6,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,150 · Food and Beverage: $2,845 · Travel and Lodging: $10.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,150.00 |
| Food and Beverage | $2,844.80 |
| Travel and Lodging | $10.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $7,017.84 | 2022-2025 | Nayzilam, Briviact, Fintepla |
| Livanova USA, INC. | $551.51 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Acadia Pharmaceuticals INC | $418.26 | 2023-2025 | Daybue |
| Jazz Pharmaceuticals INC. | $233.30 | 2022-2025 | Epidiolex |
| Neurelis, INC. | $187.60 | 2020-2025 | Valtoco |
| Greenwich Biosciences, INC. | $182.77 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $165.30 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $111.16 | 2019-2022 | |
| Ptc Therapeutics, INC. | $104.44 | 2021 | |
| Eisai INC. | $103.17 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $101.00 | 2019-2023 | Koselugo |
| Amneal Pharmaceuticals LLC | $70.53 | 2019-2023 | Lyvispah |
| Zogenix INC. | $67.79 | 2020-2021 | |
| Travere Therapeutics, INC. | $44.43 | 2019-2022 | |
| Immedica Pharma US, INC. | $41.40 | 2023-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aquestive Therapeutics, INC. | $40.89 | 2019-2024 | |
| Biogen, INC. | $37.60 | 2020-2024 | Spinraza |
| Sarepta Therapeutics, INC. | $35.06 | 2021-2024 | Elevidys |
| Sumitomo Pharma America, INC. | $34.90 | 2024 | Aptiom |
| Astrazeneca Pharmaceuticals Lp | $32.85 | 2021 | |
| Mallinckrodt Enterprises LLC | $29.56 | 2019 | |
| Aprecia Pharmaceuticals, LLC | $22.65 | 2021 | |
| Genzyme Corporation | $22.12 | 2019 | |
| Genentech USA, INC. | $21.61 | 2020 | |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $19.38 | 2019 | |
| Mallinckrodt Hospital Products INC. | $19.33 | 2020 | |
| Biomarin Pharmaceutical INC. | $11.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Zach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.